Malignant cells generally acquire some immune escape mechanisms for clonal expansion. Immune escape mechanisms also contribute to the failure of graft-versus-leukemia (GVL) effect after allogeneic hematopoietic stem cell transplantation (allo-SCT). Infant leukemias with mixed-lineage leukemia (MLL) rearrangement have a remarkably short latency, and GVL effect after allo-SCT has not been clearly evidenced in these leukemias. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-and FasL-mediated cytotoxic pathways play important roles in cytotoxic T-lymphocyte-and natural killer cell-mediated antitumor immunity and optimal GVL activity. We investigated the in vitro sensitivity of MLL-rearranged acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) cells to TRAIL-and FasL-mediated cytotoxicity. Most of cell lines and primary leukemia cells were highly resistant to TRAIL primarily owing to low cell-surface expression of death receptors in ALL and simultaneous expression of decoy receptors in AML. Nearly half of cell lines and majority of primary leukemia cells showed low sensitivity to FasL. These results suggest that resistance to death-inducing ligands, particularly to TRAIL, could be one of the mechanisms for a rapid clonal expansion and a poor sensitivity to the GVL effect in infant leukemias with MLL rearrangement.
Introduction
Majority of acute leukemias in infant, either acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML), posses a chromosomal translocation affecting the 11q23 chromosome region which specifically involves the mixed-lineage leukemia (MLL) gene. [1] [2] [3] Most pediatric leukemias with MLL rearrangement clearly have a remarkably short latency. 1, 4 MLL gene rearrangement is also associated with secondary leukemias of patients previously treated with the topoisomerase II inhibitors. 4 The latency of these secondary leukemias is similarly very short. 4 Of note, the concordance rate of leukemia with MLL rearrangement in infant monozygotic twins approximates to 100%, 1, 4 and identical breakpoint in the MLL gene was shared in these pairs of identical twin infants with concordant ALL. 1, 4 Moreover, the unique and clonotypic MLL fusion gene was detectable in neonatal blood spots for Guthrie cards from non-twined individuals who subsequently developed ALL. 1, 4 These observations indicate not only that MLL fusion is generated in utero but also that MLL fusion proteins could be capable of inducing leukemic transformation with few, if any, secondary mutations. 2, 3, 4 Greaves et al. 4 speculate that an MLL fusion protein somehow promotes rapid transition to full-blown disease in patients via very rapid clonal expansion, genetic instability or inhibition of DNA damage repair. In general, for clonal expansion of malignancies, tumor cells often have acquired strategies that escape immune surveillance of the hosts. 5, 6 Immune escape mechanisms also contribute to the failure of graft-versus-leukemia (GVL) effect after allogeneic hematopoietic stem cell transplantation (allo-SCT). 7 Therefore, leukemia cells could acquire some immune escape mechanisms during leukemogenesis. A large retrospective study demonstrated that allo-SCT might not improve the clinical outcome of children with t(4;11)-positive ALL, 8 although a recent intensive chemotherapy followed by allo-SCT early in the first remission reported to improve the prognosis of infant ALL with MLL rearrangement. 9 Considering these circumstances, leukemias with MLL rearrangement might acquire some mechanisms to escape immune surveillance, which might result in a relatively poor sensitivity to GVL effect after allo-SCT.
Immune surveillance against tumors is mediated by innate and adaptive components of cellular immunity, which mainly consists of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). 5, 6, 10 It has recently been demonstrated that death receptor ligands including FasL and tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) play an important role in CTL-and NK cell-mediated antitumor immunity.
11-17 TRAIL induces apoptosis in a variety of tumor cells 17 upon binding with its death-inducing receptors, DR4 18 and DR5. 19 In contrast, two other cell-surface TRAIL receptors, DcR1 19, 20 and DcR2, 21 lack a functional death domain and compete with DR4 and DR5 for TRAIL binding as 'decoy receptors'. Preferential expression of the decoy receptors on normal cells is one of the mechanisms underlying the preferential proapoptotic action of TRAIL against tumor cells but not normal cells. Recent investigations emphasize a critical role for TRAIL in immune surveillance against tumors. Both neutralization of TRAIL by blocking antibodies 16 and disruption of TRAIL expression by gene targeting 15 promoted carcinogen-induced tumor development in mice. Large numbers of these tumors were TRAIL sensitive, 16 suggesting a crucial antitumor activity of TRAIL during tumor development. Accordingly, acquisition of TRAIL resistance in early tumorigenesis could promote tumor expansion. Moreover, in bone marrow transplantation models using TRAIL-deficient mice, TRAIL was required for optimal graft-versus-tumor activity by donor T cells, although it played little or no role in the development graft-versus-host disease (GVHD). 17 In the present study, we investigated the susceptibility of infant leukemias with MLL rearrangement to recombinant human soluble TRAIL (rhsTRAIL), and found their resistance to TRAIL, suggesting that it may be at least partly responsible for their rapid clonal expansion and relatively poor sensitivity to GVL effect after allo-SCT.
Materials and methods

Leukemia cell lines, patients' samples and reagents
Nine ALL cell lines with the 11q23 translocations listed in Table 1 were used in this study. KOCL33 but not other eight ALL cell lines with the 11q23 translocations has point mutation of D835 of the FLT3 gene and resultant strong constitutive activation of STAT5. 22 Nalm1 was used as a control for TRAIL sensitivity, whereas Jurkat was used as a control for FasL sensitivity. Six Ph1-positive ALL cell lines (KOPN30bi, -57bi, -66bi, -72bi, YAMN73 and -91), which were previously reported, 23 and 15 B-precursor ALL cell lines including seven with t(1;19) (697, KOPN34, -36, -60, -63, YAMN90 and -92), two with t(17;19) (UOC-B1 and HAL-O1), one with t(12;21) (Reh) and five with others (KOPN35, -61, -62, -79 and -84) were also used. For the use of patient's samples, informed consent was obtained from the patients' parents. Mononuclear cells (blasts 495%) that had been isolated from bone marrow aspirates or peripheral blood samples by Ficoll-Hypaque density centrifugation were stored in liquid nitrogen with 15% dimethyl sulfoxide in fetal calf serum (FCS). For experiments, each sample was thawed, washed with serum-free Roswell Park Memorial Institute (RPMI) 1640 medium and resuspended in RPMI 1640 with 10% FCS. rhsTRAIL (Killer TRAIL), rhsFasL (SUPER FasL) and BAY 11-7085, an inhibitor-kB (IkBa) phosphorylation inhibitor, 24 were purchased from Alexis Biochemicals (San Diego, CA, USA). Z-Val-Ala-DL-Asp (OMe)-fluoromethylketone (z-VAD-fmk), a caspase inhibitor, and N-acetyl-Leu-Leu-norLeu-al (LLnL), a proteasome inhibitor, 23 were purchased from Enzyme Systems Products (Livermore, CA, USA) and Sigma-Aldrich (Tokyo, Japan), respectively. SN50, a cell permeable nuclear factor-kB (NF-kB) inhibitory peptide, and its control peptide SN50M 23 were purchased from Biomol (Plymouth Meeting, PA, USA).
H-thymidine uptake assay
Cells (5 Â 10 4 cells/well) were cultured in triplicate in 200 ml of RPMI 1640 medium supplemented with 10% FCS in a flat-bottomed 96-well plate. The plates were incubated for the indicated periods of time, pulsed for the last 6 h of the incubation with 3 H-thymidine (1 mCi/well) and harvested onto glass-fiber filters. The level of radioactivity incorporated into DNA was measured by liquid scintillation counting. The effects of rhsTRAIL and rhsFasL were determined in a 42-h incubation in the absence or presence of threefold diluted concentrations (11, 33 and 100 ng/ml) of rhsTRAIL or rhsFasL. A neutralizing anti-TRAIL monoclonal antibody (mAb) (RIK-2; 10 mg/ml), 23 z-VAD-fmk (20 mM), or LLnL (2.5 mM), BAY 11-7085 (1 mM) and SN50 (200 ng/ml) was used to block the activity of rhsTRAIL, caspases or NF-kB, respectively. The % inhibition by TRAIL or FasL was calculated as follows: (1À((c.p.m. of treated well)/ (c.p.m. of untreated well))) Â 100.
Viability and apoptosis assays
Cells (1 Â 10 5 cells/well) were cultured in the presence of rhsTRAIL or rhsFasL at 100 ng/ml, and harvested at 24 h. Viability was determined by staining with trypan blue. The D viability (%) was calculated as follows: (% viability in the absence of rhsTRAIL or rhsFasL)À(% viability in the presence of rhsTRAIL or rhsFasL). To detect the early apoptotic event, cells (4 Â 10 5 cells/ml) were cultured in the absence or presence of rhsTRAIL or rhsFasL (100 ng/ml), harvested at 12 h, stained with fluorescein isothiocyanate (FITC)-conjugated Annexin-V (MBL, Nagoya, Japan) and analyzed by flow cytometry (FACS Calibur, BD Biosciences, San Jose, CA, USA). 23 (1 Â 10 6 cells) were incubated with 1 mg of biotinylated control mouse IgG1 or mAb on ice for 30 min. After washing, the cells were incubated with phycoerythrinconjugated streptavidin (Biomeda, Foster City, CA, USA) on ice for 30 min, and then analyzed by flow cytometry. The relative florescence intensity (RFI) was calculated as the ratio of the mean fluorescence intensity of specific staining to that of control staining.
Real-time polymerase chain reaction analysis
Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacture's directions. Reverse transcription was performed with 3 mg of total RNA, random hexamer (Amersham Bioscience, Buckinghamshire, UK) and Superscript II reverse transcriptase (Invitrogen) at conditions recommended by the manufacture, and then incubated with 1 ml of RNase (Invitrogen) at 371C for 20 min. For quantitative real-time polymerase chain reaction (PCR) of DR4 and DR5 transcripts, triplicated samples containing 9 ml of cDNA with 10 ml of Taqman Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and 1 ml of 20 Â Assayson-demand Gene Expression Product (DR4, Hs 00269492_m1; DR5, Hs 00366272_m1; Applied Biosystems) were pre-incubated at 501C for 2 min and subsequently at 951C for 10 min. Amplification was obtained by 40 cycles of reaction at 951C for 15 s and 601C for 1 min. Fluorescence data were quantitatively analyzed on ABI Prism 7500 Sequence Detection System (Applied Biosystems). Nalm1, a TRAIL-sensitive chronic myelogenous leukemia blast crisis (CML-BC)-derived cell line which expresses DR4 and DR5, 23 was used for control. As internal control, quantitative real-time PCR for glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Hs 99999905_m1; Applied Biosystems) was performed.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) for NF-kB was performed according to the previously described method. 25 Ten micrograms of nuclear extracts was incubated in a 5 ml of binding buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, 4% glycerol) and 0.05 mg/ml nonspecific competitor DNA for 15 min. Then, 32 P-labeled NF-kB-specific oligonucleotide (5 0 -AGTTGAGGGGACTTTCCCAGGC-3 0 ) was added, and the mixture was incubated on ice for 20 min. For competitive inhibition, 100-fold molar excess of the unlabeled oligonucleotide was added to the reaction mixture. For supershift analysis, anti-p50 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to the nuclear extracts and incubated for 30 min before the reaction. The samples were subjected to 6% non-denaturing polyacrylamide gel electrophoresis.
Statistics
The Kruskal-Wallis test, a non-parametric, distribution-free statistics test, was performed for the comparison of the differences among three groups of observations. When the P-value for this overall comparison was significant (o0.05), post hoc pairwise comparisons were carried out with the joint ranking Wilcoxon's rank sum test. Both tests were performed as two-tailed test.
Results
Sensitivities of cell lines derived from B-precursor ALL with MLL rearrangement to TRAIL
We first examined the susceptibility of nine B-precursor ALL cell lines with MLL rearrangement to rhsTRAIL by 3 H-thymidine uptake assay ( Figure 1a and Table 1 ). rhsTRAIL markedly inhibited the growth of Ph1-positive Nalm1 cells. 23 In contrast, eight of the nine ALL cell lines with MLL rearrangement were highly resistant to TRAIL, and only KOCL33, which exceptionally has FLT3-D835 mutation, 22 was partially susceptible to TRAIL. The anti-leukemic activity of TRAIL against KOCL33 was specific and dependent on the activation of caspases, as both RIK-2, a neutralizing antibody against TRAIL, and z-VAD-fmk, a broad caspase inhibitor, almost completely blocked the activities of TRAIL (Figure 1b ). Upon 12-h incubation with rhsTRAIL (100 ng/ml), the percentage of Annexin-V-positive apoptotic cells in KOCL33 moderately increased, whereas that in KOCL44 and KOCL58 did not considerably change ( Figure 1c ). We also examined the susceptibility to rhsFasL ( Figure 1a and Table 1 ). FasL markedly inhibited the growth of KOCL44, KOCL50 and KOPN1 as well as Jurkat cells. KOCL51, KOCL58 and KOCL69 were partially susceptible to FasL, whereas KOCL33, KOCL45 and KOPB26 were highly resistant to FasL. Upon incubation with FasL, the percentage of Annexin-V-positive apoptotic cells in KOCL44 and KOCL58 markedly or moderately increased, respectively, whereas that in KOCL33 did not considerably change ( Figure 1c) .
We compared the TRAIL sensitivities between ALL cell lines with MLL rearrangement and other B-precursor ALL cell lines (Figure 1d ), and found the significant difference among three groups. ALL cell lines with MLL rearrangement were relatively and significantly more resistant to TRAIL than Ph1-positive ALL cell lines 23 and the other 15 cell lines, respectively.
Expression of TRAIL receptors on B-precursor ALL cell lines with MLL rearrangement
To explore the mechanisms of TRAIL resistance, we first analyzed the cell-surface expression of TRAIL receptors by flow cytometry using specific mAbs. 23 The specificity of each mAb is shown against BHK cell lines transfected with respective human TRAIL receptors cDNAs (Figure 2a ). The RFIs in each cell line are summarized in Table 2 . DR4 was weakly detectable on KOCL58, but was undetectable on the eight other cell lines ( Figure 2b and Table 2 ). DR5 was clearly detectable on KOCL33, and weakly detectable on KOCL45 and KOPN1, but was almost undetectable (RFI o1.2) on the six other cell lines ( Figure 2b and Table 2 ). DcR1 and DcR2 were virtually undetectable on all cell lines (Table 2) , although we could not completely rule out the possibility of low levels of DcR2 expression because of the limited reaction by the antibody (Figure 2a ). In contrast, Fas was expressed at substantial levels (RFIX2.0) on all cell lines with MLL rearrangement except for KOCL45 ( Figure 2b and Table 2) . We compared the cell-surface expression of DR4 and DR5 between ALL cell lines with MLL rearrangement and the other B-precursor ALL cell lines (Figure 2c ), but did not find statistically significant difference among three groups. However, when KOCL33, TRAIL-resistance in leukemia with MLL fusion T Inukai et al exceptionally having FLT3-D835 mutation, 22 was excluded from analysis, we found that the level of DR5 expression on ALL cell lines with MLL rearrangement was significantly and relatively lower than that on Ph1-positive ALL cell lines 23 and the other 15 cell lines, respectively.
We next analyzed the expression of DR4 and DR5 transcripts by real-time reverse transcriptase-PCR (RT-PCR) ( Table 2) . Strong correlation between the cell-surface expression of DR4 and DR5 and the levels of their transcripts was revealed. The coefficients of correlation for DR4 and DR5 were 0.649 H-thymidine uptake was evaluated for the last 6 h of the incubation. The TRAIL-sensitive Ph1-positive leukemia cell line, Nalm1, and the FasL-sensitive T-cell leukemia cell line, Jurkat, are included as controls (dotted lines). ALL cell lines with t(11;19) are shown as closed symbols, and those with t(4;11) and t(9;11) are shown as open or dark symbols, respectively. All data are represented as the mean of triplicate samples. All standard errors (s.e.'s) were less than 10% (data not shown). (b) Effects of anti-TRAIL mAb and z-VAD-fmk on TRAIL-induced growth inhibition of KOCL33. KOCL33 was cultured for 42 h in the presence or absence of rhsTRAIL (100 ng/ml) with or without neutralizing anti-TRAIL mAb (RIK-2; 10 mg/ml) (left panel) or z-VAD-fmk (20 mM) (right panel), and % inhibition of the 
These results suggest that in the majority of ALL cell lines with MLL rearrangement, the resistance to TRAIL can be explained by low cell-surface expression of DR4 and DR5 owing to low levels of transcripts. We then compared the levels of DR4 and DR5 transcripts between ALL cell lines with MLL rearrangement and the other B-precursor ALL cell lines (Figure 2d) , and found the significant difference in the level of DR4 transcript but not in that of DR5 transcript. The level of DR4 transcript in the ALL cell lines with MLL rearrangement was significantly lower than that in Ph1-positive ALL cell lines and the other 15 cell lines. Abbreviations: ALL, acute lymphoblastic leukemia; MLL, mixed-lineage leukemia; RFI, relative florescence intensity; TRAIL, tumor necrosis factorrelated apoptosis-inducing ligand. a RFI was determined by the ratio of mean fluorescence intensity of specific staining to that of control staining. 7 and 10 ). These results suggest that the interaction between TRAIL and DR5 induces NF-kB activation in KOCL33. Then, we examined whether an NF-kB inhibitor could modulate the sensitivity to TRAIL. Each of ALL cell lines with MLL rearrangement was pre-incubated for 3 h with the proteasome inhibitor, LLnL, 23 followed by 42-h incubation with rhsTRAIL, in which 3 H-thymidine uptake was assessed during the last 6 h of the incubation (Figure 3b) . In partially TRAILsensitive KOCL33, % inhibitions of TRAIL and LLnL were approximately 30 and 50%, respectively, and % inhibition of their combination was enhanced to 80%, indicating an additive effect. 27 A similar experiment was also performed in KOCL33 using BAY 11-7085, a pharmacological inhibitor of IkBa phosphorylation, 24 and SN50, a cell-permeable inhibitory peptide of nuclear translocation of NF-kB. 23 Both BAY 11-7085 and SN50, but not mutant control peptide SN50M, enhanced sensitivity to TRAIL (Figure 3b) , indicating that the inhibitors of NF-kB activation enhance the anti-leukemic activity of TRAIL in KOCL33. LLnL alone showed inhibitory effect in all cell lines (data not shown). Additive effect of TRAIL and LLnL was observed less remarkably in KOCL50, KOCL45 (Figure 3b ) and KOPB26 (data not shown). In contrast, as representatively shown in KOCL58 and KOPN1 (Figure 3b ), LLnL did not enhance the anti-leukemic activity of TRAIL in the other five cell lines. These results indicate that the inhibitors of NF-kB activation had a very limited effect on the anti-leukemic activity of TRAIL in most of ALL cell lines with MLL rearrangement.
TRAIL sensitivities of primary ALL and AML cells with MLL rearrangement
We next examined the anti-leukemic activity of TRAIL against primary leukemia cells using 12 samples from ALL with MLL rearrangement listed in Table 3 . After 12-h incubation of leukemia cells from three cases in the presence of 100 ng/ml rhsTRAIL, an increase in the percentage of Annexin-V-positive apoptotic cells was 20% in Case 1, but only negligible in Cases 2 and 3 ( Figure 4a ). Each of all samples was cultured for 24 h in the absence or presence of rhsTRAIL, and changes in viability were determined. The viability of the cells in five (42%) of the 12 cases significantly decreased in the presence of rhsTRAIL (Table 3) , but the mean of D viability (%) in these sensitive cases was only 21% (range, 10-30%) (Figure 4b ). The degree of sensitivity to TRAIL was not correlated with a particular type of translocation ( Table 3) . As the patients relapsed early except for Case 12, the impact of in vitro sensitivity to TRAIL on the prognosis of the patients was not clear. In Ph1-positive ALL, the viability of primary leukemia cells significantly decreased in the presence of rhsTRAIL in six (60%) of the 10 cases and the mean of D viability in the sensitive cases reached 37% (range, 27-50%) (Figure 4b ). 23 As a result, among the TRAIL-sensitive cases, the D viability was significantly smaller in ALL cases with MLL rearrangement than in the Ph1-positive ALL cases, indicating that primary leukemia cells from ALL with MLL rearrangement showed resistance or only limited sensitivity to anti-leukemic activity of rhsTRAIL. Then, we examined DR4/DR5 expression by flow cytometry (Figure 4c and Table 3 ). In the 12 MLL-rearranged ALL cases, the RFIs of DR4 and DR5 were undetectable or less than 1.5 even in the cases weakly TRAIL-resistance in leukemia with MLL fusion T Inukai et al sensitive to TRAIL, whereas in the TRAIL-sensitive Ph1-positive ALL cases the RFI of DR4 and/or DR5 was 1.5 or higher. 23 We also examined the susceptibility of primary leukemia cells to FasL (Figure 4a and Table 3 ). The viability of the cells significantly decreased in the presence of rhsFasL in three of the 12 cases with MLL-rearranged ALL, and the mean of D viability in the sensitive cases was 13% (range, 8-20%). In Ph1-positive ALL, nine of the 10 cases were resistant to FasL and the D viability of the sensitive case was 10%. 23 In flow cytometric analysis for Fas, the RFI was 1.5 or higher on primary leukemia cells from ALL with MLL rearrangement (Figure 4c and Table 3) .
We next examined primary leukemia cells using 10 samples from infant AML cases with MLL rearrangement listed in Table 3 . The percentage of Annexin-V-positive apoptotic cells modestly increased in Cases 2 and 6, but almost not in Case 7 (Figure 4a ). The viability of the cells significantly decreased in the presence of rhsTRAIL in four (40%) of the 10 cases (Table 3) , but the mean of D viability (%) in the four sensitive cases was only 13% (range, 11-14%) (Figure 4b) . Thus, the D viability was relatively smaller in TRAIL-sensitive AML cases with MLL rearrangement than in the TRAIL-sensitive Ph1-positive ALL cases. 23 Of note, the RFIs of DR4 and/or DR5 were 1.5 or higher in seven cases including five TRAIL-resistant cases, and the RFI of DcR1 was 1.5 or higher in five of six DR4/DR5-positive cases tested ( Figure 4c and Table 3 ). This suggests that the expression of decoy receptor could be responsible for TRAIL resistance in the DR4/DR5-positive MLL-rearranged AML cases. We also examined the susceptibility to FasL (Figure 4a and Table 3 ), but all cases were resistant to the anti-leukemic activity of rhsFasL. The RFI of Fas was always 4.0 or higher (Figure 4c and Table 3 ).
Discussion
The B-precursor ALL cell lines and primary leukemia cells with MLL rearrangement were significantly resistant to rhsTRAIL, whereas the majority of other B-precursor ALL cell lines including Ph1-positive ones were sensitive to rhsTRAIL. The majority of ALL cell lines and primary leukemia cells with MLL rearrangement had barely detectable cell-surface expression of DR4 and DR5 owing to low levels of transcripts, and this seems to be the primary factor responsible for their resistance to TRAIL. The primary leukemia cells from the patients with MLL-rearranged AML were also resistant to rhsTRAIL. Of note, high level of cell-surface DcR1 expression was confirmed in most of DR4/DR5-positive primary AML cells with MLL rearrangement, and this seems to be the primary factor responsible for their resistance to TRAIL. KOCL33 showed TRAIL-resistance in leukemia with MLL fusion T Inukai et al moderate resistance to rhsTRAIL despite its apparent expression of DR5 and no expression of decoy receptors. As only KOCL33 has the FLT3-D835 mutation, 22 altered signaling by the FLT3-D835 mutation might involve in the mechanism for TRAIL-resistance in KOCL33.
The general resistance of leukemia with MLL rearrangement to TRAIL in vitro suggests that these leukemic cells might be relatively resistant to TRAIL-mediated anti-leukemic activities of CTLs and NK cells in vivo. As TRAIL has been predominantly implicated in innate and adoptive tumor immune surveillance, 10, [13] [14] [15] [16] TRAIL resistance could help early leukemias with MLL rearrangement to escape from immunoselection pressure and promote further clonal expansion. TRAIL has also been implicated in GVT/GVL effects after allo-SCT, 17 suggesting Table 2 were cultured for 12 h with or without rhsTRAIL (100 ng/ml) or rhsFasL (100 ng/ml), and then stained with FITC- Table 2 were stained with control mouse IgG (open histograms) or anti-human DR4, DR5, DcR1, DcR2 or Fas mAb (shaded histograms), and analyzed by flow cytometry. The RFI is indicated in each panel.
TRAIL-resistance in leukemia with MLL fusion T Inukai et al that TRAIL resistance in leukemia with MLL rearrangement is responsible for low sensitivity to GVL activities by CTLs and NK cells. We previously showed that TRAIL can efficiently induce apoptosis in CML-BC and Ph1-positive ALL, 23 which might be responsible for the better prognosis of these leukemias after allo-SCT. 28 The one of most interesting issues is how leukemia cells with MLL rearrangement acquire a unique feature of TRAIL resistance. As normal tissues usually show resistance to TRAIL, TRAIL sensitivity in neoplasm would be basically acquired during tumorigenesis. The origin of B-precursor ALL with MLL rearrangement has been considered to be multipotential hematopoietic stem cells, and all four TRAIL receptors were reported to be undetectable on quiescent CD34 þ hematopoietic progenitors. 29 This suggests a model that the absence or low level of death receptor expression in MLL-rearranged B-precursor ALL cells simply reflects the nature of their affected hematopoietic progenitors. Moreover, considering the recent report that expression of all four TRAIL receptor is inducible during monocytic differentiation in normal hematopoiesis, 29 simultaneous expression of DR4/DR5 and decoy receptors in MLL-rearranged AML might also reflect the nature of their affected myelomonocytic progenitors. Alternatively, leukemias with MLL rearrangement might somehow escape from upregulation of DR4/DR5 and/or downregulation of decoy receptors during leukemogenesis.
Finally, we tested whether the TRAIL sensitivity is enhanced by the inhibition of NF-kB activity. The pretreatment with NF-kB inhibitors significantly enhanced sensitivity to TRAIL in KOCL33 but not or only modestly in the other ALL cell lines with MLL rearrangement. Thus, further exploration is necessary to overcome the TRAIL resistance of ALL with MLL rearrangement. 
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